Evidence map›Paper›PMID 41170836›Full record

ArticleInternational journal of cancer2026

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience.

Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Mario HlevnjakMolecular Precision Oncology Program, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Sabine HeubleinDepartment of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.
Verena ThewesNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Lukas WagenerNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Constantin PixbergNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Carlo FremdNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Laura MichelNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Christian MaurerNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Lars BuschhornNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Nicola DikowInstitute of Human Genetics, Heidelberg University, Heidelberg, Germany.
Fangyoumin FengMolecular Precision Oncology Program, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Stefan FröhlingNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-7907-4595
Christel Herold-MendeDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.
Steffen HirschInstitute of Human Genetics, Heidelberg University, Heidelberg, Germany.
Chen HongMolecular Precision Oncology Program, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Daniel HübschmannNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Lena JassowiczDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Polina KozyulinaMolecular Precision Oncology Program, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Katrin PfützeDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Richard F SchlenkDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Hans-Peter SinnInstitute for Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-2836-6699
Katharina SmetanayDepartment of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.
Christoph SpringfeldDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Albrecht StenzingerInstitute for Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0003-1001-103X
Celina WagnerNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Stephan WolfNext Generation Sequencing Core Facility, German Cancer Research Center DKFZ, Heidelberg, Germany.
Andreas TrumppGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Dirk JägerDepartment of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Oliver ZivanovicDepartment of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.
Marc ZapatkaDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID https://orcid.org/0000-0001-8287-5967
Andreas SchneeweissNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.
Peter LichterNational Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-2960-5279

Funding

Bundesministerium für Bildung und Forschung #01KD2206German Cancer Aid #70113450German Cancer Aid #70116282National Center for Tumor Diseases Heidelberg, Molecular Precision Oncology Program
6 · The paper itself

Abstract

CATCH is a prospective precision oncology registry trial that exploits whole-genome/exome- and RNA-sequencing to enable actionable biomarker detection in metastatic breast cancer (mBC) patients of any subtype. We herein report long-term follow-up of the first 558 patients consecutively recruited into CATCH in a monocentric setting between June 2017 and October 2021. Main outcome measures were the rate of implementation of molecular tumor board (MTB) recommended treatments and treatment response as assessed by disease control rate, objective response rate and PFS ratio. Out of the recruited patients, 412 (54.9% HR+/HER2-, 31.3% TNBC, 6.8% HR-/HER2+ and 7.0% HR+/HER2+) were reviewed in the MTB. An appropriate molecularly guided anti-cancer treatment as recommended by MTB was implemented in 183 (44.4%) patients. Gene expression and computationally derived composite biomarkers further expanded treatment options in up to every second patient as compared to genomic sequencing data alone. The outcome was assessed in 152 patients and showed a Disease Control Rate (DCR) of 58.6% and an Objective Response Rate (ORR) of 27.0%. One in three patients (32.8%) showed at least a 50% longer PFS with molecularly guided therapy compared to the previous standard therapy. Notably, 86.4% of the MTB-driven implementations were off-label. CATCH highlights the impact of whole-genome/exome in combination with RNA sequencing to detect clinically relevant biomarkers in mBC. Omics-guided targeted therapy in a real-world setting allows high treatment implementation rates yielding outcome benefit for one-third of the patients.

Indexed as

Biomarkers, TumorBreast NeoplasmsPrecision MedicineAdultAgedAged, 80 and overExome SequencingFemaleFollow-Up StudiesGene Expression ProfilingGenomicsHumansMiddle AgedNeoplasm MetastasisProspective StudiesRegistriesBiomarkers, Tumorbreast cancerprecision oncologyreal‐world studywhole genome sequencingwhole transcriptome sequencing

Identifiers

PMID41170836
PMCPMC12811195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.